Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NERV Stock Forecast 2026-2027
$4.27
Current Price
$196.14M
Market Cap
Buy 1
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to NERV Price Targets
+227.9%
To High Target of $14.00
+75.6%
To Median Target of $7.50
+63.9%
To Low Target of $7.00
NERV Price Momentum
-9.5%
1 Week Change
-4.5%
1 Month Change
+114.6%
1 Year Change
+6.2%
Year-to-Date Change
-65.7%
From 52W High of $12.46
+142.6%
From 52W Low of $1.76
📊 TOP ANALYST CALLS
Did NERV Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Minerva Neurosciences is one of their latest high-conviction picks.
Latest NERV Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, NERV has a neutral consensus with a median price target of $7.50 (ranging from $7.00 to $14.00). The overall analyst rating is Buy (6.7/10). Currently trading at $4.27, the median forecast implies a 75.6% upside. This outlook is supported by 1 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jason N. Butler at Citizens, projecting a 227.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NERV Analyst Ratings
1
Buy
2
Hold
0
Sell
NERV Price Target Range
Low
$7.00
Average
$7.50
High
$14.00
Current: $4.27
Latest NERV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NERV.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 15, 2026 | Citizens | Jason N. Butler | Market Outperform | Initiates | $14.00 |
| Mar 12, 2026 | HC Wainwright & Co. | Neutral | Maintains | $N/A | |
| Nov 6, 2025 | HC Wainwright & Co. | Neutral | Maintains | $N/A | |
| Feb 26, 2025 | HC Wainwright & Co. | Neutral | Reiterates | $N/A | |
| Nov 6, 2024 | HC Wainwright & Co. | Neutral | Reiterates | $N/A | |
| Aug 7, 2024 | HC Wainwright & Co. | Neutral | Maintains | $N/A | |
| May 2, 2024 | HC Wainwright & Co. | Neutral | Maintains | $N/A | |
| Feb 27, 2024 | HC Wainwright & Co. | Neutral | Reiterates | $N/A | |
| Aug 2, 2023 | HC Wainwright & Co. | Neutral | Maintains | $N/A | |
| May 16, 2023 | HC Wainwright & Co. | Neutral | Reiterates | $N/A | |
| May 2, 2023 | HC Wainwright & Co. | Neutral | Reiterates | $N/A | |
| Mar 9, 2023 | HC Wainwright & Co. | Neutral | Reiterates | $N/A | |
| Nov 10, 2022 | HC Wainwright & Co. | Neutral | Downgrade | $N/A | |
| Oct 17, 2022 | JMP Securities | Market Perform | Downgrade | $N/A | |
| Mar 4, 2022 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $5.00 |
| Jun 8, 2020 | HC Wainwright & Co. | Buy | Maintains | $10.00 | |
| Dec 19, 2019 | JMP Securities | Market Outperform | Maintains | $18.00 | |
| Dec 19, 2019 | H.C. Wainwright | Buy | Reiterates | $N/A | |
| Dec 19, 2019 | HC Wainwright & Co. | Buy | Reiterates | $20.00 | |
| Sep 25, 2019 | Chardan Capital | Buy | Initiates | $N/A |
Minerva Neurosciences Inc. (NERV) Competitors
The following stocks are similar to Minerva Neurosciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
NERV
Minerva Neurosciences
mkt cap
219.90M
Minerva Neurosciences Inc. (NERV) Financial Data
Minerva Neurosciences Inc. has a market capitalization of $196.14M with a P/E ratio of 2.5x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of +208.5%.
Valuation Metrics
Market Cap
$196.14M
Enterprise Value
$188.16M
P/E Ratio
2.5x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+39.3%
Current Ratio
17.6x
Debt/Equity
-0.2x
ROE
+208.5%
ROA
-27.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Minerva Neurosciences Inc. (NERV) Business Model
About Minerva Neurosciences Inc.
What They Do
Develops treatments for central nervous system diseases.
Business Model
Minerva Neurosciences Inc. operates as a clinical-stage biopharmaceutical company, focusing on the development and commercialization of innovative therapies for central nervous system disorders. The company generates revenue through the successful development and potential commercialization of its lead product candidates, such as roluperidone for schizophrenia and MIN-301 for Parkinson's disease.
Additional Information
Founded in 2007 and headquartered in Burlington, Massachusetts, Minerva emphasizes innovative clinical trial designs that are closely aligned with patient benefits. The company aims to address significant unmet medical needs in chronic neurologic and psychiatric conditions, positioning itself in the biotechnology sector of healthcare.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
7
CEO
Dr. Remy Luthringer Ph.D.
Country
United States
IPO Year
2014
Website
www.minervaneurosciences.comMinerva Neurosciences Inc. (NERV) Latest News & Analysis
Latest News
Quick Summary
A panel of experts in psychiatry and neuroscience has been appointed to oversee the Phase 3 trial of roluperidone and the company's broader R&D strategy.
Why It Matters
The appointment of experts for the Phase 3 trial of roluperidone suggests increased credibility and potential for successful outcomes, impacting the company's stock value and future growth in the mental health sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
2 months ago
Quick Summary
Minerva Neurosciences, Inc. (Nasdaq: NERV) will have CEO Remy Luthringer participate in the 2026 Jefferies Global Healthcare Conference from June 2-4 in New York.
Why It Matters
Minerva's participation in a major healthcare conference highlights its visibility and credibility in the biotech sector, potentially attracting investor interest and impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Minerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
1 month ago
Quick Summary
Minerva Neurosciences (NERV) may be poised for a rebound as it enters oversold territory, with analysts revising earnings estimates higher, suggesting potential for a trend reversal.
Why It Matters
Minerva Neurosciences (NERV) may be poised for recovery due to oversold conditions and analyst upgrades, signaling potential for price appreciation and improved investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Minerva Neurosciences (NERV) has been upgraded to a Zacks Rank #2 (Buy), indicating increasing optimism about its earnings prospects.
Why It Matters
Minerva Neurosciences' upgrade to Zacks Rank #2 signals increased earnings potential, suggesting improved investor sentiment and potential stock price appreciation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
2 months ago
Quick Summary
Minerva Neurosciences has initiated a Phase 3 trial for roluperidone, targeting negative symptoms of schizophrenia. Previous trials showed no safety concerns.
Why It Matters
The initiation of a Phase 3 trial for roluperidone highlights potential advancement in schizophrenia treatment, impacting Minerva Neurosciences' stock and market position in a high-demand sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Minerva Neurosciences has initiated a Phase 3 trial for roluperidone, the only late-stage drug for schizophrenia's negative symptoms, with efficacy data expected in 2H 2027.
Why It Matters
Minerva's roluperidone, the only late-stage candidate for schizophrenia's negative symptoms, shows promise with positive trial results, potentially leading to significant market impact by 2027.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About NERV Stock
What is Minerva Neurosciences Inc.'s (NERV) stock forecast for 2027?
Based on our analysis of 3 Wall Street analysts, Minerva Neurosciences Inc. (NERV) has a median price target of $7.50. The highest price target is $14.00 and the lowest is $7.00.
Is NERV stock a good investment in 2027?
According to current analyst ratings, NERV has 1 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.27. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NERV stock?
Wall Street analysts predict NERV stock could reach $7.50 in the next 12 months. This represents a 75.6% increase from the current price of $4.27. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Minerva Neurosciences Inc.'s business model?
Minerva Neurosciences Inc. operates as a clinical-stage biopharmaceutical company, focusing on the development and commercialization of innovative therapies for central nervous system disorders. The company generates revenue through the successful development and potential commercialization of its lead product candidates, such as roluperidone for schizophrenia and MIN-301 for Parkinson's disease.
What is the highest forecasted price for NERV Minerva Neurosciences Inc.?
The highest price target for NERV is $14.00 from Jason N. Butler at Citizens, which represents a 227.9% increase from the current price of $4.27.
What is the lowest forecasted price for NERV Minerva Neurosciences Inc.?
The lowest price target for NERV is $7.00 from at , which represents a 63.9% increase from the current price of $4.27.
What is the overall NERV consensus from analysts for Minerva Neurosciences Inc.?
The overall analyst consensus for NERV is neutral. Out of 3 Wall Street analysts, 1 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $7.50.
How accurate are NERV stock price projections?
Stock price projections, including those for Minerva Neurosciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 18, 2026 2:44 AM UTC